SEC Form S-8 filed by Instil Bio Inc.
$TIL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
As filed with the Securities and Exchange Commission on March 4, 2025 Registration No. 333- | ||
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Instil Bio, Inc.
(Exact name of Registrant as specified in its charter)
Delaware | 83-2072195 | |||||||
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||
3963 Maple Avenue, Suite 350
Dallas, TX 75219
(Address of principal executive offices)(Zip code)
2021 Equity Incentive Plan
2021 Employee Stock Purchase Plan
(Full title of the plans)
Bronson Crouch
Chief Executive Officer
Instil Bio, Inc.
3963 Maple Avenue, Suite 350
Dallas TX 75219
(972) 499-3350
(Name and address of agent for service)(Telephone number, including area code, of agent for service)
Copies to:
Divakar Gupta Courtney M.W. Tygesson Cooley LLP 55 Hudson Yards New York, NY 10001 Telephone: (212) 479-6000 Facsimile: (212) 479-6275 | ||
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ | Accelerated filer ☐ | ||||
Non-accelerated filer ☒ | Smaller reporting company ☒ | ||||
Emerging growth company ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Pursuant to General Instruction E of Form S-8, Instil Bio, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register an additional 326,294 shares of common stock under the 2021 Equity Incentive Plan and an additional 65,259 shares of common stock under the 2021 Employee Stock Purchase Plan, pursuant to the provisions of each plan which provide for annual automatic increases in the number of shares of common stock reserved for issuance under each respective plan. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
The contents of the Registrant’s Registration Statements on Form S-8, filed with the Commission on April 20, 2021 (File No. 333-255355) and March 21, 2024 (File No. 333-278154), are incorporated by reference into this Registration Statement.
PART II
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE
The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
(a) The Registrant’s Annual Report on Form 10-K (File No. 001-40215) for the fiscal year ended December 31, 2024, filed with the Commission on March 4, 2025;
(b) The Registrant’s Current Report on Form 8-K (File No. 001-40215) filed with the Commission on January 14, 2025, to the extent the information in such report is filed and not furnished; and
(c) The description of the Registrant’s Common Stock which is contained in the Registrant’s Registration Statement on Form 8-A filed on March 15, 2021 (File No. 001-40215) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as updated by the description of the Registrant’s securities filed as Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Commission on March 7, 2022, including any amendment or report filed for the purpose of updating such description.
All documents, reports and definitive proxy or information statements filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL
As of the date hereof, GC&H Investments, LLC, an entity consisting of current and former partners and associates of Cooley LLP, beneficially holds an aggregate of 6,370 shares of the Registrant’s common stock.
ITEM 8. EXHIBITS
Exhibit Number | Description | Incorporated by Reference | Filed Herewith | |||||||||||||||||
Schedule Form | File Number | Exhibit | Filing Date | |||||||||||||||||
4.1 | 10-K | 001-40215 | 3.1 | March 21, 2024 | ||||||||||||||||
4.2 | 8-K | 001-40215 | 3.2 | March 23, 2021 | ||||||||||||||||
4.3 | S-1 | 333-253620 | 10.2 | March 15, 2021 | ||||||||||||||||
4.4 | S-1 | 333-253620 | 10.4 | March 15, 2021 | ||||||||||||||||
5.1 | X | |||||||||||||||||||
23.1 | X | |||||||||||||||||||
23.2 | Consent of Cooley LLP (included in Exhibit 5.1) | X | ||||||||||||||||||
24.1 | Power of Attorney (included in signature pages of Registration Statement) | X | ||||||||||||||||||
107 | X | |||||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dallas, State of Texas, on this 4th day of March, 2025.
Instil Bio, Inc.
By: /s/ Bronson Crouch
Name: Bronson Crouch
Title: Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Bronson Crouch and Sandeep Laumas, M.D., and each of them, as his true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution, for him or her and in his name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this registration statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii) act on and file any supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and (iv) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
| Name | Position | Date | ||||||
| /s/ Bronson Crouch | Chief Executive Officer and Director (Principal Executive Officer) | March 4, 2025 | ||||||
| Bronson Crouch | ||||||||
| /s/ Sandeep Laumas, M.D. | Chief Financial Officer and Chief Business Officer (Principal Financial and Accounting Officer) | March 4, 2025 | ||||||
| Sandeep Laumas, M.D. | ||||||||
| /s/ Gwendolyn Binder, Ph.D. | Director | March 4, 2025 | ||||||
| Gwendolyn Binder, Ph.D. | ||||||||
| /s/ Neil Gibson, Ph.D. | Director | March 4, 2025 | ||||||
| Neil Gibson, Ph.D. | ||||||||
| /s/ George Matcham, Ph.D. | Director | March 4, 2025 | ||||||
| George Matcham, Ph.D. | ||||||||
| /s/ R. Kent McGaughy, Jr. | Director | March 4, 2025 | ||||||
| R. Kent McGaughy, Jr. | ||||||||